Jonathan Baell: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 25: | Line 25: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 15:47, 17 March 2025
Jonathan Baell is a distinguished pharmaceutical scientist and academic, known for his significant contributions to the field of medicinal chemistry. He is currently a Professor of Medicinal Chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University, Australia.
Early Life and Education[edit]
Baell completed his Bachelor of Science degree, majoring in chemistry, from the University of Melbourne. He later pursued his PhD in Medicinal Chemistry from the same university.
Career[edit]
Baell began his career as a medicinal chemist at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), where he worked on various drug discovery projects. He later joined the Walter and Eliza Hall Institute of Medical Research (WEHI), where he led the Medicinal Chemistry group.
In 2010, Baell joined the Monash Institute of Pharmaceutical Sciences as a Professor of Medicinal Chemistry. His research focuses on the design and synthesis of new drugs for treating various diseases, including cancer, malaria, and neurodegenerative diseases.
Contributions[edit]
Baell is best known for his work on "PAINS" (Pan-Assay Interference Compounds), which are compounds that often give false positive results in high-throughput screening (HTS) assays. His research in this area has significantly improved the efficiency and reliability of drug discovery processes.
Awards and Honors[edit]
Baell has received numerous awards for his contributions to medicinal chemistry, including the Royal Australian Chemical Institute (RACI) Adrien Albert Award.
References[edit]
<references />
